Yazen's systematic approach and impressive growth trajectory demonstrate what is needed to make a real difference in obesity care. I am excited to join forces with their international team and strengthen our position in Denmark.
We are thrilled to work with Medstart's skilled team and continue our shared mission of improving the lives of people with obesity. Together, we aim to provide patients in Denmark and Norway with the best possible care.
Obesity remains a significant global challenge, with millions affected and substantial societal costs. Yazen's model integrates digital healthcare, specialist teams, and innovative GLP-1 and GLP-1/GIP medications.
The acquisition follows Yazen's recent € 19.5 million investment round, enabling the company to expand its offerings and reach new markets.
Collection
[
|
...
]